Crown Bioscience Inc.
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers:
- Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856
- Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;12(6):e0179808, https://doi.org/10.1371/journal.pone.0179808
The FATZO model mirrors human disease conditions by providing polygenic obesity and metabolic patterns of hyperglycemia and hyperinsulinemia to support insulin resistance similar to the metabolic disease in patients with insulin resistance / type 2 diabetes.
"Crown Bioscience is committed to validating the translatability of our models and providing novel scientific advancements that are representative of human conditions of obesity and type 2 diabetes," said Jim Wang, Sr. Vice President, Cardiovascular Metabolic Research, Crown Bioscience. "Our innovations will continue to enable breakthroughs for preclinical drug discovery and development."
For more information on Crown Bioscience's commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. firstname.lastname@example.org
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Inspiration Mining Corporation20.2.2018 21:37 | pressemeddelelse
Inspiration Mining to File a Complaint with OSC Against Stockwatch
Aurora Solar Technologies Inc.20.2.2018 21:09 | pressemeddelelse
Aurora Releases Third Quarter Results
Bermuda Business Development Agency (BDA)20.2.2018 16:38 | pressemeddelelse
Bermuda Principles event merges science and business
Elite Capital & Co. Limited20.2.2018 15:43 | pressemeddelelse
Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy
Corel20.2.2018 15:28 | pressemeddelelse
New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success
Cisco20.2.2018 14:02 | pressemeddelelse
Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum